Medical News

RSS

Bristol-Myers Squibb, Mead Johnson Nutrition announce share exchange offer preliminary results

Bristol-Myers Squibb Company and Mead Johnson Nutrition Company announced today that based on preliminary results the offer by Bristol-Myers Squibb to exchange up to 170,000,000 shares of common stock of Mead Johnson for outstanding shares of Bristol-Myers Squibb common stock that are validly tendered and not validly withdrawn was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, on December 17, 2009.

18 Dec 2009

Nu Skin Enterprises launches the new ageLOC Future Serum

Nu Skin Enterprises, Inc. introduced the new ageLOC Future Serum to more than 10,000 sales representatives at its launch event in Japan. Japanese distributors were eager to be in the first market to fully launch one of the company's new ageLOC skin care products that targets the sources of aging by resetting youth gene clusters to a more youthful pattern. The ageLOC products are marketed as 'genLOC' in Japan.

18 Dec 2009

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Leerink Swann, the leading healthcare-focused investment banking firm, today announced the availability of the firm’s 2010 healthcare investment outlook report.

18 Dec 2009

Allied Healthcare International increases its presence across London Boroughs, secures 3-year contract

Allied Healthcare International Inc., a leading provider of flexible healthcare staffing services in the United Kingdom, has secured a three-year contract with the London Borough of Richmond Council in the United Kingdom.

18 Dec 2009

Danaher offers GBP 50 million pounds for Genetix Group acquisition

Danaher Corporation announced today its intention to make a recommended cash takeover offer, through an indirect wholly owned subsidiary, to acquire all of the issued and to be issued shares of Genetix Group plc for 85 pence per share implying an aggregate price of approximately GBP 50 million pounds (USD $82 million) net of cash acquired.

From Danaher 18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

Congress lifts federal ban on needle exchange programs

The Minnesota Independent: "An appropriations bill passed by Congress last weekend is being hailed by public health advocates for ending funding for abstinence-until-marriage sex education and eliminating the ban on federal funding for needle exchange programs" (Birkey, 12/17).

18 Dec 2009

ABC News should focus more on integrity, says National Center for Public Policy Research

ABC News should focus less on Charlie Gibson and Diane Sawyer and more on integrity, says the National Center for Public Policy Research, which just completed an advertising review of ABC's nightly World News.

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Liberator Medical Holdings reports record net revenues for fiscal year 2009

Liberator Medical Holdings, Inc. announced net revenues for fiscal year 2009 of $25,818,000, representing an increase of $16,268,000, or 170.3%, compared with fiscal year 2008. The increase in sales occurred in the mail order segment of its business. The increase was due to a substantial direct-response advertising campaign to obtain new mail order customers.

18 Dec 2009

MOCON declares quarterly dividend of $0.09 per share

MOCON, Inc. announced today that on December 17, 2009, its Board of Directors declared a quarterly cash dividend of nine cents ($0.09) per share, payable on February 19, 2010, to shareholders of record on February 5, 2010.

18 Dec 2009

LifeMasters Supported SelfCare completes sale of its assets to StayWell Health Management

LifeMasters Supported SelfCare, Inc. today announced that it has completed the sale of substantially all of its assets to StayWell Health Management. The sale was completed pursuant Section 363 of the bankruptcy code at an auction held on December 14, 2009. The bankruptcy court approved the sale order December 17 and the sale of assets is expected to close within three weeks.

18 Dec 2009

Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Ocimum Biosolutions, a leading integrated genomics company, today announced that it ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009, a ranking of the 500 fastest growing technology companies in Asia Pacific. Rankings are based on percentage revenue growth over three years. In addition to ranking on Deloitte’s Technology Fast 500, Ocimum ranked fourth on the Technology Fast 50 India Program, which is a ranking of the 50 fastest growing technology firms in India.

18 Dec 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, announced today that it is setting up Niacinamide and 3-Cyanopyridine plant of 10,000 TPA each, expected to be ready by end of 2010.

18 Dec 2009

Tips for holiday partying with healthier options

The Greenbelt Marriott has collected tips from its experts on throwing a great holiday party with healthier options and easy-to-do decorating that won’t break the bank. The hotel is also helping guests stay in shape through the $700,000 expansion of its fitness center, due to be completed early next year.

18 Dec 2009

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Patheon announces fiscal 2009 fourth-quarter and full-year financial results

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for the fourth quarter and full year ended October 31, 2009.

18 Dec 2009

Safe living guidelines for transplant recipients

Keeping pets healthy can reduce infection risks for people who have received solid organ transplants and veterinarians should be seen as an integral part of the healthcare team. That's just one of the key pieces of advice from a safe living article published in an infectious diseases supplement in the American Journal of Transplantation.

18 Dec 2009

First Edition: December 18, 2009

The highlights from today's headlines focus on continuing movement in the Senate toward a pre-Christmas health overhaul vote -- but many questions about its cost, and how many votes it can attract, persist.

18 Dec 2009

Medical News

Bristol-Myers Squibb, Mead Johnson Nutrition announce share exchange offer preliminary results

Nu Skin Enterprises launches the new ageLOC Future Serum

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Allied Healthcare International increases its presence across London Boroughs, secures 3-year contract

Danaher offers GBP 50 million pounds for Genetix Group acquisition

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Congress lifts federal ban on needle exchange programs

ABC News should focus more on integrity, says National Center for Public Policy Research

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Liberator Medical Holdings reports record net revenues for fiscal year 2009

MOCON declares quarterly dividend of $0.09 per share

LifeMasters Supported SelfCare completes sale of its assets to StayWell Health Management

Ocimum Biosolutions ranked 42nd on the Deloitte Technology Fast 500 Asia Pacific 2009

Jubilant Organosys announces new facility for Niacinamide and 3-Cyanopyridine

Tips for holiday partying with healthier options

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Patheon announces fiscal 2009 fourth-quarter and full-year financial results

Safe living guidelines for transplant recipients

First Edition: December 18, 2009

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News